Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

PHASE2RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Gallbladder Carcinoma
Interventions
DRUG

gemcitabine and oxaliplatin.

GEMOX Conventional chemotherapy:gemcitabine and oxaliplatin.

DRUG

Afatinib

Target therapy Drug: afatinib

Trial Locations (2)

Unknown

RECRUITING

Renji hospital, Shanghai Jiaotong University School of Medicine, Shanghai

RECRUITING

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Shanghai Zhongshan Hospital

OTHER

collaborator

Ruijin Hospital

OTHER

collaborator

RenJi Hospital

OTHER

collaborator

Qilu Hospital of Shandong University

OTHER

collaborator

The First Affiliated Hospital of Anhui Medical University

OTHER

collaborator

Shanghai East Hospital of Tongji University

OTHER

collaborator

Changshu Affiliated Hospital of Soochow University

OTHER

collaborator

Qinghai People's Hospital

OTHER

collaborator

The Second People's Hospital of Baoshan, Yunnan Province

UNKNOWN

collaborator

Lanzhou University Second Hospital

OTHER

collaborator

The Affiliated Hospital of Inner Mongolia Medical University

OTHER

collaborator

The First People's Hospital of Nantong

UNKNOWN

lead

Shanghai Jiao Tong University School of Medicine

OTHER